Wyeth says that it has been served with a subpoena from the US attorney’s office in Massachusetts, seeking documents relating to the pricing of its Protonix (pantoprazole) anti-ulcerant.

Specifically, the company has been asked to provide documents from January 2000 to the present relating to its quarterly calculations of the average manufacturer price and best price, which are used to calculate rebates due to state Medicaid programmes, for Protonix oral tablets and intravenously administered products.

Wyeth, which revealed the subpoena in a US Securities and Exchange Commission filing yesterday, says that it understands that other pharmaceutical companies have received similar subpoenas from the same US attorney.